The Revolving Door Has a Billion-Dollar Handle

Let me tell you a story about how money moves in America.

Not the kind of money most of us see. The other kind. The kind that doesn't move through paychecks or direct deposits or anything so pedestrian as working for it. It moves through board seats and advisory roles and milestone payments and equity stakes in companies with names so generic you'd scroll right past them — and by the time it lands, someone is already on a yacht calling it a return on investment.

This story starts in 2022, ends six days ago with a $1.55 billion acquisition, and features a cast of characters so perfectly assembled that if you tried to pitch it as a TV show, your agent would tell you it's too on the nose.

Buckle up.

Act One: Name Your Company Nothing

In 2022, biotechnology venture firm ARCH Venture Partners founded a company called Vaccine Company, Inc.

That's the name. Vaccine Company. Not named after its founders. Not named after its technology. Not named after a Greek god or a Latin root or a made-up word that sounds vaguely scientific. Just: Vaccine Company, Incorporated.

This is either a stroke of genius — make the company so generically named that nobody finds it in a search — or the most confident display of "we are not worried about scrutiny" in the history of corporate naming conventions. Possibly both.

Joining ARCH as investors were Luma Group, Pfizer Ventures, Wellcome Trust, Lilly Ventures, and Global Health Investment Corporation.

Pfizer Ventures. Lilly Ventures. Two of the largest pharmaceutical corporations on the planet — through their dedicated investment arms — putting money into a startup vaccine company that one of them would eventually buy for $1.55 billion.

They were investing in their own future acquisition. They just hadn't filed the paperwork yet.

The company was headquartered in Bethesda, Maryland, employed 21 people, and raised $132 million in private capital.

Twenty-one people. In Bethesda. With nine figures in backing from Pfizer and Lilly.

I want you to really sit with that ratio for a moment.

Act Two: Assemble the Roster

A startup with no product, no revenue, and a name you could generate by pressing the spacebar is only as credible as the people attached to it. Vaccine Company understood this assignment completely.

The CFO was a former Biden White House COVID adviser. The chief medical officer spent roughly 18 years at Fauci's own agency — the National Institute of Allergy and Infectious Diseases — and helped oversee Moderna's first COVID vaccine trial.

And then there was the scientific advisory group.

In 2023, shortly after leaving government service, Dr. Anthony Fauci joined the scientific advisory group of Vaccine Company, Inc. His own curriculum vitae confirms it: "Member, Scientific Advisory Group, Vaccine Company, Inc., 2023-present."

The man who ran America's infectious disease response for nearly four decades, who turned down $5-7 million a year offers from pharma corporations after retirement — his words, in a CBS News interview — did agree to join the advisory board of a Bethesda startup backed by Pfizer and Lilly.

What the CV does not mention is what consulting fees, shares, options, or any other compensation he received for this role.

Just the title. Very clean. Very tidy.

Act Three: Let the Taxpayer Handle the Risky Part

Here is where your money enters the story, unbidden and unannounced.

In 2024, the Biden administration's Advanced Research Projects Agency for Health — ARPA-H — awarded Vaccine Company more than $28 million in federal grant funding, with up to $49 million available, to develop vaccines against viral families associated with emerging infections and potential pandemics.

Now to be fair — and I will be fair, because accuracy matters even when the facts are already doing plenty — this is not unusual in isolation. The federal government routinely funds early-stage biotech research because it is expensive, risky, and private capital generally refuses to touch it until someone else proves it works.

The wrinkle here is that the company requesting your tax dollars already had Pfizer Ventures and Lilly Ventures among its backers. It had a former White House COVID adviser as its CFO. An 18-year NIAID veteran as its CMO. And the most recognizable name in American infectious disease on its scientific advisory board.

This is not a scrappy team of outsiders asking the government to take a chance on them. This is the government's own former people asking the government to fund the part that private money finds too risky — so that private money can collect the upside when it isn't risky anymore.

Senator Joni Ernst demanded an investigation into how ARPA-H vetted the company before awarding the funds, warning there were "alarm bells going off" over the process. The earlier inquiry, however, focused on other personnel. Nobody had yet identified Fauci's position on the advisory board. That detail emerged separately. Quietly. Much later.

That's one way things come out.

Act Four: The Exit Nobody Announced in Advance

On May 26, 2026, Eli Lilly announced it had entered into a definitive agreement to acquire Vaccine Company, Inc. for up to $1.55 billion in cash — structured as an upfront payment plus milestone-based payouts tied to clinical and commercial progress.

The buyer: Eli Lilly.

The same Eli Lilly whose corporate venture arm — Lilly Ventures — had been an investor in Vaccine Company since the day it was founded.

Lilly helped fund the company. The company received $28 million in taxpayer grants. The federal funding derisked the technology. Then Lilly bought the company.

If you're waiting for the twist, there isn't one. That's just the sequence.

A former ARPA-H program manager publicly celebrated the deal, writing that the combination of federal oversight and funding had helped Vaccine Company "derisk their technology platform enough for this exit."

He said it. In public. In a press statement. With his name attached.

The federal grant — your money — was deployed, by his own cheerful account, to make the company ready for a private acquisition that would benefit its equity holders. The same equity holders whose identities and compensation arrangements remain, at the time of this writing, not fully known to the public that funded the whole exercise.

Act Five: The Incomplete Ledger

Here is a short list of things we still do not know:

What Anthony Fauci was paid — in fees, equity, options, or any other instrument — for his role on the Vaccine Company scientific advisory board.

What percentage of the $1.55 billion acquisition flows to which equity holders and in what amounts.

Whether anyone involved in awarding the ARPA-H grant had prior or subsequent relationships with the company or its investors.

The complete cap table of a 21-person company that received tens of millions in public funding and sold for over a billion dollars.

None of this is necessarily illegal. The revolving door is legal. Advisory board compensation is legal. A corporation's venture arm investing in a company that parent later acquires is legal.

Legal and transparent are not synonyms. I looked it up.

Act Six: The System Isn't Broken. It's Working Exactly As Designed.

Here is where most people assume there must be some secret, some deliberate act of concealment, some shadowy coordination happening in a room somewhere with the lights off.

There isn't. And that's what makes it interesting.

The reason Fauci's Vaccine Company compensation remains unknown isn't because someone is hiding it particularly cleverly. It's because the system was specifically not designed to capture it. Every gap in the disclosure framework is a gap that was always there — it just matters more when a $1.55 billion acquisition is sitting on the other side of it.

Here's how the gaps actually work:

The disclosure obligation ends the day you leave.

The OGE Form 278e — the public financial disclosure that senior federal officials file annually — applies to current federal employees. Once someone leaves government service, the obligation ends. Full stop. Fauci filed his last required disclosure as a federal employee. What he earns, holds equity in, or collects as a private citizen after that point is under no mandatory public reporting requirement whatsoever. The six-figure deposits that watchdog groups flagged in his 2023 financials appeared because he voluntarily provided information — not because anyone made him.

He left in December 2022. He joined Vaccine Company's advisory board in 2023. The timeline is not subtle. The disclosure requirement, however, had already clocked out.

And here's the irony that deserves its own moment:

Fauci didn't have to file anything. The obligation was gone the day he left. But he filed a financial disclosure anyway — voluntarily — which has been widely cited as evidence that he's being transparent.

Except the disclosure he voluntarily filed is the same disclosure that shows six-figure deposits with no detailed sourcing. The same disclosure that doesn't capture private company equity. The same disclosure that was never designed to reveal advisory board compensation, stock options, or milestone payments from a pre-acquisition startup.

So what we have is a man who went out of his way to file a form he didn't have to file, that doesn't show the things people most want to know, structured in a way that makes the gaps look like compliance.

In accounting we call that a disclosure that discloses nothing. In Washington they apparently call it transparency.

The voluntary filing didn't open the books. It closed the conversation.

Private company equity is essentially invisible.

If you receive stock options or an equity stake in a private company — which Vaccine Company was, right up until the moment Lilly bought it — there is no public registry, no SEC filing, no mandatory disclosure mechanism that captures it. Public Citizen has specifically identified the lack of emphasis on unearned income and the structural gaps in the Ethics in Government Act of 1978 as insufficient checks on conflicts of interest. Private company equity sits directly in that gap. It exists, it accumulates value, and unless the holder chooses to disclose it or the company goes public, it is invisible to everyone outside the cap table.

Vaccine Company never went public. It went straight from private to acquired. That's a very clean path for equity that nobody outside the deal will ever fully account for.

The royalty gap is a documented, named problem that Congress hasn't fixed.

Under current law, royalties received by federal employees in connection with their official duties are not required to appear on mandatory public financial disclosure forms. NIH employees alone received 54,151 royalty payments totaling $325.8 million between 2009 and 2021. Rand Paul introduced the Royalty Transparency Act in 2024 specifically to close this gap. It got out of committee. It has not passed. The gap remains open, functional, and apparently not urgent enough to address.

Advisory board compensation has no post-government disclosure requirement.

Post-employment restrictions under federal ethics law prohibit former senior officials from lobbying their former agencies for one to two years after departure. That's the rule everyone knows. What the rule does not cover is sitting on a scientific advisory board — providing expertise, lending a famous name, attending quarterly meetings, and collecting whatever compensation the company has agreed to provide in return. That is not lobbying. It does not trigger the restriction. And the compensation for it — fees, equity, options, milestones — flows without any mandatory disclosure mechanism once the person has cleared the revolving door.

The GAO flagged the entire system as outdated — in December 2024.

The Government Accountability Office published a report in December 2024 noting that the Office of Government Ethics had not conducted a comprehensive evaluation of the financial disclosure program since 2005, and that Congress had not updated the core requirements as of October 2024.

The system designed to catch conflicts of interest in the federal government was last seriously examined when the iPhone didn't exist, private equity was a fraction of its current size, and nobody had heard of ARPA-H. It has not been meaningfully updated since. And yet here we are, asking it to account for a $1.55 billion biotech acquisition involving a former federal official whose post-retirement compensation is structured in exactly the vehicles the system was never built to see.

This isn't a conspiracy. It's a org chart. And the org chart has very convenient blind spots.

The Part Nobody Wants to Say Out Loud

Fauci said in a 2024 CBS News interview that he was offered positions paying $5 million, $6 million, $7 million a year from pharmaceutical corporations and private equity upon leaving government. He said he turned them down.

What he did not turn down, his own CV confirms, was a seat on the scientific advisory board of a company backed by Pfizer and Lilly that just sold for $1.55 billion.

His federal financial disclosures show his household financial assets grew by more than $3 million in 2023, his first year out of government. The disclosures did not show direct investments in individual vaccine manufacturers or pharmaceutical companies.

A watchdog group obtained his financial disclosure showing the household earned more than $3.5 million in 2023 — including multiple six-figure deposits whose sources were not detailed in the documents.

Not detailed. In documents designed to provide detail. In a system designed to provide transparency.

The IRS would like a word.

What We Actually Know vs. What We Don't

Let's be precise — because I am an accountant and precision is how I'm wired.

What is documented:
Fauci joined the advisory board in 2023. The company received $28 million in federal grants in 2024. Lilly — which had invested since founding — bought it for up to $1.55 billion in May 2026. A former ARPA-H official credited the federal funding with making the exit possible.

What is not documented:
Whether Fauci held equity or options that made him a direct financial beneficiary of the acquisition. What the six-figure deposits in his 2023 disclosure represent. The full cap table of the company.

In accounting, an undisclosed material interest is a problem.

In Washington, it's a Thursday.

The Bigger Picture

This post is not an argument against vaccines. The Epstein-Barr research Vaccine Company was pursuing — targeting a virus linked to multiple sclerosis and several cancers — is genuinely important work and worth funding.

This post is about the mechanism. The sequence. The way federal money flows toward connected entities, derisks the technology on the public's tab, and then privatizes the upside for a small circle of people whose full financial arrangements we are not entitled to see.

The system doesn't require villains. It just requires everyone to be playing the game the system was built to reward — and it rewards it very, very well.

Meanwhile the rest of us are out here arguing about whether we owe $2,400 because we skipped Step 2 of our W-4.

The math, as always, is indifferent to your feelings.